tbuckley/cabot-search huggingface dataset:
CAN WE ALWAYS PREVENT DYSPEPTIC SYMPTOMS WITH HELICOBACTER PYLORI ERADICATION IN PEPTIC ULCER PATIENTS
Authors: Miroslava Katicic, Slavica Naumovski-Mihalic, Tajana Filipec, Marija Prskalo, Vasna Colic-Cvrlje, Branko Papa, Mirjana Ticak, Bruno Skurla, Branka Sabaric
Journal: Gut (2004)
DOUBLE-HEADED SMALL BOWEL CAPSULE ENDOSCOPY: REAL-WORLD EXPERIENCE AT A TERTIARY REFERRAL CENTRE
Authors: DE Yung, S Douglas, J Brzeszczynska, JN Plevris, A Koulaouzidis
Journal: Endoscopy (2019)

Capsule endoscopy (CE) is a well-established mode of investigation for small bowel (SB) pathology. This study aims to characterise the potential benefits of using double-headed capsules (vs conventional single-headed ones) in a real-world cohort of patients referred for CE. We present initial results from a single centre as part of a multicentre British study.
ENDOSCOPIC PREDICTION OF INVASION DEPTH BY CONVENTIONAL COLONOSCOPY IN EARLY COLORECTAL CANCER. A PROSPECTIVE STUDY IN PERU 2014 – 2018
Authors: L Marin Calderon, JB Medina Morales, F Palacios Salas, P Bardalez Cruz, J Vasquez Quiroga, E Alva Alva, JE Medina Morales, M Davalos Moscol
Journal: Endoscopy (2019)

Endoscopic resection has been established as the treatment of choice for adenomas and cancer colorectal early (ECRC), with minimal risk of lymph node metastasis. Hence, the tumoral invasion prediction might help to determine the best therapeutic approach. The aim of the study is to assess the prediction of tumor invasion by means of conventional colonoscopy in early colorectal neoplastic lesions.
Endoscopic radial incision combined with dexamethasone therapy for stricture of the esophagus caused by Crohn’s disease
Authors: Yan Jia, Cheng Chen, Peng Jin, Dongliang Yu, Luping Wang, Shirong Li, Jianqiu Sheng
Journal: Endoscopy (2019)

A 35-year-old man who had experienced substernal pain for 3 years and dysphagia for 6 months was admitted to our hospital. Laboratory data were negative for the autoantibodies and T-SPOT.TB test. A chest computed tomography scan showed thickening of the esophageal wall. Colonoscopy indicated multiple ulcers in the terminal ileum and ileocecal valve ([Fig. 1]). Pathology indicated moderate active chronic colitis with erosion and crypt abscess ([Fig. 2]). Gastroscopy demonstrated scarring changes and severely ulcerated lesions of the esophagus ([Fig. 3]). The pathology revealed only granulation tissue ([Fig. 4]). The esophageal ulcers were longitudinal with annular stenosis. Ultrasonic gastroscopy indicated that the lesions involved the submucosa and muscular layer. Therefore, the patient was diagnosed as having Crohn’s disease (esophagus involved, stenosis type, active, moderate).
Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition
Authors: William P. Esler, Gregory J. Tesz, Marc K. Hellerstein, Carine Beysen, Raja Sivamani, Scott M. Turner, Steven M. Watkins, Paul A. Amor, Santos Carvajal-Gonzalez, Frank J. Geoly, Kathleen E. Biddle, Julie J. Purkal, Mark Fitch, Clare Buckeridge, Annette M. Silvia, David A. Griffith, Matthew Gorgoglione, Lauren Hassoun, Suzana S. Bosanac, Nicholas B. Vera, Timothy P. Rolph, Jeffrey A. Pfefferkorn, Gabriele E. Sonnenberg
Journal: Science Translational Medicine (2019)

De novo lipogenesis is essential for human sebum production, and increased lipogenic flux accounts for excessive sebum production in acne vulgaris.
Abstract 17477: NCKAP1L: A Novel Target Gene Linked to Survival in Pulmonary Arterial Hypertension Patients
Authors: Nael Aldweib, Stephen Chan, Bob Stearman, Howard Weiner, Hemant Tiwari, Raymond Benza
Journal: Circulation (2017)

Introduction: Variable response to PAH therapeutics suggests that genetic differences may influence survival. As such, we hypothesized that enhanced activation of RhoBTB1 is associated with increas...
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Authors: Oliver Distler, Kristin B. Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D. Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves, Emmanuelle Clerisme-Beaty, Susanne Stowasser, Kay Tetzlaff, Masataka Kuwana, Toby M. Maher
Journal: New England Journal of Medicine (2019)

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD.
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Authors: James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead, Deborah A. Freedman-Cass
Journal: Journal of the National Comprehensive Cancer Network (2019)

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction
Authors: Avinainder Singh, Ankur Gupta, Bradley L. Collins, Arman Qamar, Keri L. Monda, David Biery, J. Antonio G. Lopez, Sarah D. de Ferranti, Jorge Plutzky, Christopher P. Cannon, James L. Januzzi, Marcelo F. Di Carli, Khurram Nasir, Deepak L. Bhatt, Ron Blankstein
Journal: Journal of the American College of Cardiology (2019)
Modulation of CD22 Antigen Density Improves Efficacy of CD22 Chimeric Antigen Receptor (CAR) T Cells Against CD22lo B-Lineage Leukemia and Lymphoma
Authors: Sneha Ramakrishna, Sang M Nguyen, Haiying Qin, Steven L Highfill, Ira Kraft, John Shern, Zachary Walsh, Dimiter Dimitrov, Terry J Fry
Journal: Blood (2017)
Targeting the highly abundant circular RNA circSlc8a1 in cardiomyocytes attenuates pressure overload induced hypertrophy
Authors: Tingsen Benson Lim, Edita Aliwarga, Tuan Danh Anh Luu, Yiqing Peter Li, Shi Ling Ng, Lavenniah Annadoray, Stephanie Sian, Matthew Andrew Ackers-Johnson, Roger Sik-Yin Foo
Journal: Cardiovascular Research (2019)

We and others have previously described the expression landscape of circular RNA (circRNA) in mouse and human hearts. However, the functional relevance of many of these abundantly expressed cardiomyocyte circRNA remains to be fully explored. Among the most abundant circRNA, one stems from the sodium-calcium exchanger gene, Slc8a1, exon 2 locus. Because of its very high abundance in cardiomyocytes we investigated the possible role of circSlc8a1 in the heart.We performed a miRNA screen using an array of 752 miRNAs with RNA recovered from a pull-down of endogenous cardiomyocyte circSlc8a1. MicroRNA-133a (miR-133a), with a prior well-recognized role in cardiac hypertrophy, was highly enriched in the fraction of circSlc8a1 pull-down (adjusted P-value < 0.001). We, therefore, followed-up validation of the functional interaction between circSlc8a1 and miR-133 using luciferase assays and reciprocal pull-down assays. In vivo, AAV9-mediated RNAi knockdown of circSlc8a1 attenuates cardiac hypertrophy from pressure-overload, whereas forced cardiomyocyte specific overexpression of circSlc8a1 resulted in heart failure. Molecular analyses showed targets of miR-133a including serum response factor (Srf), connective tissue growth factor (Ctgf), adrenoceptor beta 1 (Adrb1), and adenylate cyclase 6 (Adcy6) to be regulated by circSlc8a1-directed intervention of knockdown and overexpression.In summary, circSlc8a1 can function as an endogenous sponge for miR-133a in cardiomyocytes. We propose that circSlc8a1 may serve as a novel therapeutic target for cardiac hypertrophy.
PAEM COMBINED WITH ENDOSCOPIC SUBMUCOSAL HYDRO-DISSECTION AS A RESCUE THERAPY OF RECTAL FIBROTIC ADENOMA IN ILEORRECTAL ANASTOMOSIS. A CASE REPORT
Authors: J Rodríguez-Sánchez, M Sánchez Alonso, C Sánchez García, J Olmedo Camacho
Journal: Endoscopy (2019)

Subtotal colectomy with ileorrectal anastomosis (IRA) is currently the most common surgical option in young patients with familiar adenomatous polyposis (FAP). However, this surgery does not stave off suffering the appearance of lesions in the rectal remnant. In these cases, the endoscopic submucosal dissection might be a feasible option. However, drawbacks such as: extreme fibrosis and difficult manoeuvrability in rectal remnant, become this technique rather challenging. We planned to carried out a PAEM combined by ESD with pocket creation method with the purpose of overcoming these handicaps.
Chidamide ,Oral Subtype-Selective Histone Deacetylase Inhibitor (HDACI) Monotherapy Was Effective on the Patients with Relapsed or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma
Authors: Gao Yan, Hui-qiang Huang, Pengfei Li, Bai Bing, Wang Xiaoxiao, Rong Qixiang, Li Zhiming, Cai Qingqing, Wenqi Jiang
Journal: Blood (2017)
Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label <scp>OPTIMISE</scp> study
Authors: K. Reich, L. Puig, J.C. Szepietowski, C. Paul, J.P. Lacour, A. Tsianakas, C. Sieder, M. Rissler, E. Pournara, R. Orsenigo
Journal: British Journal of Dermatology (2019)

Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A.To assess the efficacy and safety of different maintenance dosing regimens of secukinumab 300 mg based on Psoriasis Area and Severity Index (PASI) response at week 24 in patients with moderate-to-severe plaque psoriasis.OPTIMISE was a randomized, open-label, rater-blinded phase IIIb study. Patients (n = 1647) received secukinumab 300 mg at baseline; weeks 1, 2, 3 and 4; and every 4 weeks (q4w) to week 24. At week 24, PASI 90 responders (≥ 90% improvement in PASI; n = 1306) were randomized to secukinumab 300 mg q4w (n = 644) or q6w (n = 662) to week 52, and PASI ≥ 75 to < 90 responders (n = 206) were randomized to secukinumab 300 mg q4w (n = 114) or q2w (n = 92) to week 52.PASI 90 response was maintained at week 52 by 85·7% of patients with q4w dosing vs. 74·9% with q6w dosing (odds ratio 1·91, 95% confidence interval 1·44-2·55). The primary end point, noninferiority of q6w vs. q4w dosing, was not met. In PASI ≥ 75 to < 90 responders, the proportion of patients with PASI 90 response at week 52 was numerically higher in the q2w vs. the q4w group (57% vs. 46·5%, respectively, P = 0·10). Heavier patients (≥ 90 kg) demonstrated numerically higher PASI 90 response with the q2w (57·1%) vs. the q4w regimen (40%, P = 0·11).Standard q4w dosing of secukinumab 300 mg is the optimal dosing regimen to achieve and maintain clear or almost clear skin. Patients with body weight ≥ 90 kg not achieving PASI 90 at week 24 may benefit from the q2w dosing regimen. What's already known about this topic? Individual responses to biologics in patients with psoriasis vary considerably and there may be a need to individualize treatment. Dose optimization strategies of currently available biologic drugs have been investigated mainly in rheumatic disorders. Secukinumab has shown long-term PASI 90/100 responses (percentage improvement in Psoriasis Area and Severity Index) to year 5 in patients with moderate-to-severe plaque psoriasis when used at the dose of 300 mg every 4 weeks. What does this study add? Standard every 4 week (q4w) dosing of secukinumab 300 mg is the optimal regimen to achieve and maintain clear or almost clear skin at week 52; the majority of the patients (85·7%) maintain PASI 90 at week 52. Superiority of intensified (q2w) dosing over the q4w regimen could not be claimed. However, patients with a higher body weight (≥ 90 kg) not achieving PASI 90 response at week 24 may benefit from q2w dosing.
Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study
Authors: Anne-Flore M. Matthijssen, Andrea Dietrich, Margreet Bierens, Renee Kleine Deters, Gigi H.H. van de Loo-Neus, Barbara J. van den Hoofdakker, Jan K. Buitelaar, Pieter J. Hoekstra
Journal: American Journal of Psychiatry (2019)

Objective: The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use. Methods: Ninety-four children and adolescents (ages 8–18 years) who had been treated in regular care with methylphenidate for more than 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg/day of extended-release methylphenidate) or gradual withdrawal over 3 weeks, to 4 weeks of placebo. The primary outcome measure was the investigator-rated ADHD Rating Scale (ADHD-RS); secondary outcome measures were the investigator-rated Clinical Global Impressions improvement scale (CGI-I) and the Conners’ Teacher Rating Scale–Revised: Short Form (CTRS-R:S). Continuous ratings were analyzed with mixed model for repeated measures analyses, and the CGI-I with a chi-square test. Results: The mean ADHD-RS scores at baseline for the continuation and discontinuation groups, respectively, were 21.4 (SD=9.7) and 19.6 (SD=8.9); after 7 weeks, the mean scores were 21.9 (SD=10.8) and 24.7 (SD=11.4), with a significant between-group difference in change over time of −4.6 (95% CI=−8.7, −0.56) in favor of the group that continued methylphenidate treatment. The ADHD-RS inattention subscale and the CTRS-R:S ADHD index and hyperactivity subscale also deteriorated significantly more in the discontinuation group. The CGI-I indicated worsening in 40.4% of the discontinuation group, compared with 15.9% of the continuation group. Conclusions: Continued treatment with methylphenidate remains effective after long-term use. Some individual patients may, however, be withdrawn from methylphenidate without deterioration. This finding supports guideline recommendations that patients be assessed periodically to determine whether there is a continued need for methylphenidate treatment.
Publisher Correction: Methionine is a metabolic dependency of tumor-initiating cells
Authors: Zhenxun Wang, Lian Yee Yip, Jia Hui Jane Lee, Zhengwei Wu, Hui Yi Chew, Pooi Kiat William Chong, Chin Chye Teo, Heather Yin-Kuan Ang, Kai Lay Esther Peh, Ju Yuan, Siming Ma, Li Shi Kimberly Choo, Nurhidayah Basri, Xia Jiang, Qiang Yu, Axel M. Hillmer, Wan Teck Lim, Tony Kiat Hon Lim, Angela Takano, Eng Huat Tan, Daniel Shao Weng Tan, Ying Swan Ho, Bing Lim, Wai Leong Tam
Journal: Nature Medicine (2019)
GP at Hand: patients are less sick than others but use services more, evaluation finds
Authors: Gareth Iacobucci
Journal: BMJ (2019)

Patients registered with Babylon’s digital service GP at Hand may be using it “more than would be expected” given their age and health status, an independent evaluation of the service has concluded.

The much delayed evaluation report from Ipsos MORI,1 which was finally presented on 23 May to Hammersmith and Fulham Clinical Commissioning Group, which holds the contract for the service, said that patients registered with GP at Hand had a higher annual rate of consultations than shown in national data.

The evaluation, produced in partnership with York Health Economics Consortium and with advisory input from Chris Salisbury, professor in primary care health at the University of Bristol, said it was unclear whether the high rate of use was due to the service’s accessibility and whether it was linked to “unmet need or supply-induced demand.”

The evaluation concluded that it “has not been able to fully address whether the [GP at Hand] model is affordable and sustainable.”

It added that the model’s benefits would not be replicable on a wider scale without “considerable …
DIFFERENTIATION OF PANCREATIC CYST TYPES BY ANALYSIS OF RHEOLOGICAL BEHAVIOR OF PANCREATIC CYST FLUID
Authors: I Khamaysi, A Abu Ammar, G Vasilyev, A Arenstein, Y Chowers, E Zussman
Journal: Endoscopy (2019)

Differentiation between mucinous and non-mucinous pancreatic cysts (PC) is exceedingly important, yet remains difficult.
AUGSBURGER ZENKER QUESTIONNAIRE – ACQUISITION OF SYMPTOMS AND MONITORING DURING FOLLOW-UP OF PATIENTS WITH ENDOSCOPIC TREATMENT OF SYMPTOMATIC ZENKER'S DIVERTICULUM
Authors: J Manzeneder, C Römmele, S Gölder, D Freuer, H Messmann
Journal: Endoscopy (2019)

The frequency and severity of symptoms of Patients with Zenker's diverticulum have been acquired by a newly developed questionnaire (Augsburger Zenker Questionnaire – AQZ). A cumulative score was generated that should help to recognize patients with symptomatic recurrence during follow-up.
TRENDS OF COLORECTAL CANCER INCIDENCE RATES IN 40 – 49 YEAR OLD SUBJECTS: FIGURES FROM THE NORTH-EAST ITALIAN CANCER REGISTRIES
Authors: C Hassan, M Zorzi, S Guzzinati, G Mazzoleni, S Piffer, D Serraino, L Dal Maso, M Rugge
Journal: Endoscopy (2019)

The American Cancer Society recently lowered the age for starting colorectal cancer (CRC) screening from 50 to 45 years. The clinical rationale behind such a strategy lies in epidemiological evidence from the USA of a rising incidence of CRC before the age of 50.
Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies
Authors: McGee, Emma E., Jackson, Sarah S., Petrick, Jessica L., Van Dyke, Alison L., Adami, Hans-Olov, Albanes, Demetrius, Andreotti, Gabriella, Beane-Freeman, Laura E., de Gonzalez, Amy Berrington, Buring, Julie E., Chan, Andrew T., Chen, Yu, Fraser, Gary E., Freedman, Neal D., Gao, Yu-Tang, Gapstur, Susan M., Gaziano, J. Michael, Giles, Graham G., Grant, Eric J., Grodstein, Francine, Hartge, Patricia, Jenab, Mazda, Kitahara, Cari M., Knutsen, Synnove F., Koh, Woon-Puay, Larsson, Susanna C., Lee, I-Min, Liao, Linda M., Luo, Juhua, Milne, Roger L., Monroe, Kristine R., Neuhouser, Marian L., O’Brien, Katie M., Peters, Ulrike, Poynter, Jenny N., Purdue, Mark P., Robien, Kim, Sandler, Dale P., Sawada, Norie, Schairer, Catherine, Sesso, Howard D., Simon, Tracey G., Sinha, Rashmi, Stolzenberg-Solomon, Rachael, Tsugane, Shoichiro, Wang, Renwei, Weiderpass, Elisabete, Weinstein, Stephanie J., White, Emily, Wolk, Alicja, Yuan, Jian-Min, Zeleniuch-Jacquotte, Anne, Zhang, Xuehong, Zhu, Bin, McGlynn, Katherine A., Campbell, Peter T., Koshiol, Jill
Journal: JNCI Journal of the National Cancer Institute (2019)

Abstract Background Tobacco and alcohol are well-established risk factors for numerous cancers, yet their relationship to biliary tract cancers remains unclear. Methods We pooled data from 26 prospective studies to evaluate associations of cigarette smoking and alcohol consumption with biliary tract cancer risk. Study-specific hazard ratios (HRs) and 95% confidence intervals (CIs) for associations with smoking and alcohol consumption were calculated. Random-effects meta-analysis produced summary estimates. All statistical tests were two-sided. Results Over a period of 38 369 156 person-years of follow-up, 1391 gallbladder, 758 intrahepatic bile duct, 1208 extrahepatic bile duct, and 623 ampulla of Vater cancer cases were identified. Ever, former, and current smoking were associated with increased extrahepatic bile duct and ampulla of Vater cancers risk (eg, current vs never smokers HR = 1.69, 95% CI = 1.34 to 2.13 and 2.22, 95% CI = 1.69 to 2.92, respectively), with dose-response effects for smoking pack-years, duration, and intensity (all Ptrend &amp;lt; .01). Current smoking and smoking intensity were also associated with intrahepatic bile duct cancer (eg, &amp;gt;40 cigarettes per day vs never smokers HR = 2.15, 95 % CI = 1.15 to 4.00; Ptrend = .001). No convincing association was observed between smoking and gallbladder cancer. Alcohol consumption was only associated with intrahepatic bile duct cancer, with increased risk for individuals consuming five or more vs zero drinks per day (HR = 2.35, 95%CI = 1.46 to 3.78; Ptrend = .04). There was evidence of statistical heterogeneity among several cancer sites, particularly between gallbladder cancer and the other biliary tract cancers. Conclusions Smoking appears to increase the risk of developing all biliary tract cancers except gallbladder cancer. Alcohol may increase the risk of intrahepatic bile duct cancer. Findings highlight etiologic heterogeneity across the biliary tract.
NEED FOR ENTEROSCOPY IN OBSCURE DIGESTIVE HAEMORRHAGE: VALIDATION OF DISCRIMINATIVE SCORE
Authors: JC Silva, J Rodrigues, R Pinho, A Rodrigues, A Ponte, M Sousa, AC Gomes, AP Silva, J Carvalho
Journal: Endoscopy (2019)

Capsule endoscopy (CE) is the first-line diagnostic method in obscure GI bleeding (OGIB). Balloon-assisted enteroscopy may also be weighted, however, its use is not always necessary. Uchida et al. score recently described for enteroscopy need after CE for OGIB, includes the type of OGIB (occult/manifest), blood transfusion and CE findings. The present study aims to evaluate and validate the proposed score as discriminator for enteroscopy need in OGIB.